1,050 Shares in United Therapeutics Corporation $UTHR Bought by Cynosure Group LLC

Cynosure Group LLC purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, Holdings Channel.com reports. The fund purchased 1,050 shares of the biotechnology company’s stock, valued at approximately $512,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. Entrust Financial LLC purchased a new stake in United Therapeutics in the fourth quarter worth $31,000. Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new stake in United Therapeutics in the fourth quarter worth $48,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $561.50, for a total transaction of $5,615,000.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,598,874. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 644,468 shares of company stock worth $363,647,822 in the last ninety days. 8.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on UTHR. Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Royal Bank Of Canada lowered their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. HC Wainwright raised their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Finally, Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $548.27 on Wednesday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The business has a fifty day moving average price of $566.12 and a 200-day moving average price of $522.52. The company has a market capitalization of $23.27 billion, a PE ratio of 20.24, a PEG ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business earned $6.63 earnings per share. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.